• NEWS & PUBLICATIONS
  • News and Media
  • Newsletters
  • Journals
  • Books
• MEMBERSHIP
  • Join/Renew
  • Benefits
  • Categories
  • Download a Member Application
  • Grants, Awards, and Scholarships
  • Access the Phantom Analysis Toolkit
  • Membership Directory
  • Chapters
  • Centers of Excellence
  • Councils
  • Member Spotlight
  • Women in Nuclear Medicine
  • SNMMI Fellow
  • SNMMI-TS Fellow
  • Council and Center Internships
• EDUCATION
  • Learning Center
  • 2024 Annual Meeting Call for Abstracts
  • Webinars
• MEETINGS & EVENTS
  • Calendar of Events
  • Webinars
  • 2023 Fall Therapeutics Conference
  • 2024 Mid-Winter Meeting
  • 2023 Annual Meeting Virtual Sesions
  • 2024 Annual Meeting Call for Abstracts
  • Nuclear Medicine & Molecular Imaging Week
• ADVOCACY
  • Coding & Reimbursement
  • Legislative Efforts
  • Government Relations News
  • Radiopharmaceutical Supply News
  • USP 825
  • Technologist State Issues
  • Position Statements
  • FDA PET Drug Manufacturing Q&A
• EVIDENCE & QUALITY
  • Clinical Guidelines and AUC
  • Quality
  • Quality and Patient Safety
  • Dose Optimization
  • About Quality & Practice
  • Dosimetry
• RESEARCH
  • Clinical Trials Network
  • Radiopharmaceutical Therapy Central
  • Radiopharmaceutical Therapy Centers of Excellence
  • Preclinical Imaging
  • Nuclear Medicine Clinical Trial Group, LLC
  • Research: Learn More
• ABOUT SNMMI
  • Strategic Plan
  • Bylaws & Procedures
  • Governance - SNMMI
  • Governance - SNMMI-TS
  • History
  • Grants, Awards, and Scholarships
  • Career Center
  • About Nuclear Medicine & Molecular Imaging
  • International Collaboration
  • Outreach
  • Support SNMMI
  • Contact Us

Press Release

• Novel PET Radiotracer Facilitates Early, Noninvasive Detection of Inflammatory Bowel Disease

  Nov 14, 2023 — A newly developed PET radiotracer can be used to create an inflammation map of the entire gastrointestinal tract, providing detailed information to accurately detect and stage inflammatory bowel disease, according to research published in JNM.

• Bone Scans Overstage Prostate Cancer at Initial Staging Compared with PSMA PET

  Nov 9, 2023 — Bone scans have been found to overstage prostate cancer at initial staging compared to PSMA PET, according to new research published in JNM.

• New AI Tool for PET Imaging Allows for High-Quality, Fully Automated Evaluation of Brain Tumors

  Oct 17, 2023 — A new artificial intelligence tool provides a fully automated, easy-to-use and objective way to detect and evaluate brain tumors, according to new research published in JNM.

• PET Imaging Validates Use of Common Cholesterol Drug to Enhance HER2-Targeted Cancer Therapy

  Oct 12, 2023 — A novel therapeutic approach combining HER2-targeted therapies with the cholesterol-lowering drug lovastatin can reduce the number of cancer treatments required to prevent tumor growth, according to research published in JNM.

• Novel Tau PET Tracer Exhibits High Sensitivity and Specificity, Allowing for Earlier Identification of Alzheimer’s Disease

  Sep 29, 2023 — A new tau PET radiotracer, F-18 SNFT-1, has been found to be more effective than existing tau PET radiotracers in identifying Alzheimer’s disease in its earliest stages, according to research published in JNM.

• Whole-Body PET/CT Predicts Response to HER2-Targeted Therapy in Metastatic Breast Cancer Patients

  Sep 28, 2023 — A new imaging agent, Ga-68-ABY-025, can predict early metabolic response to human epidermal growth factor receptor 2 (HER2)-targeted treatment in HER2-positive metastatic breast cancer patients, according to new research published in JNM.

• First Three Facilities Accredited in SNMMI/IAC Radiopharmaceutical Therapy Accreditation Program

  Sep 25, 2023 — SNMMI and the Intersocietal Accreditation Commission are pleased to announce the first three facilities to be awarded the new Radiopharmaceutical Therapy Accreditation.

• Nuclear Medicine Treatment Cures Lethal Form of Ovarian Cancer in Preclinical Setting

  Sep 18, 2023 — A new 225Ac-DOTA-based pre-targeted radioimmunotherapy system has been shown to cure a highly lethal form of advanced intraperitoneal ovarian cancer in a preclinical setting with minimal side effects, according to research published in JNM.

• JNM Publishes Consensus Statement on Patient Selection and Appropriate Use of Lu-177 PSMA-617 Radionuclide Therapy

  Sep 1, 2023 — SNMMI) has issued a new consensus statement to provide standardized guidance for the selection and management of metastatic castrate-resistant prostate cancer (mCRPC) patients being treated with Lu-177 PSMA radionuclide therapy.

• PSMA PET/CT Waives the Need for Pre-Imaging Biopsy in Elderly Patients

  Aug 14, 2023 — In elderly patients with suspected prostate cancer, PSMA PET/CT can diagnose advanced disease and aid in therapy selection without the need for a biopsy, according to new research published in JNM.

• FDA Fully Approves Leqembi for Alzheimer’s; CMS Unclear on PET Reimbursement

  Jul 10, 2023 — The FDA has granted full approval to Leqembi (lecanemab); however, CMS has not committed to reimbursement of the needed PET scans.

• SNMMI Keeps “Eye on the Patient” at 2023 Annual Meeting

  Jun 28, 2023 — SNMMI hosted nearly 8,000 physicians, technologists, pharmacists, laboratory professionals, scientists and others at its 2023 Annual Meeting, themed “Eye on the Patient,” held in Chicago, Illinois.

• Novel Radiotracer Demonstrates High Diagnostic Efficacy for Obese Patients with Coronary Artery Disease

  Jun 27, 2023 — A novel PET perfusion radiotracer, F-18 flurpiridaz, can diagnose coronary artery disease (CAD) in obese patients with a higher sensitivity and specificity compared to Tc-99m SPECT myocardial perfusion imaging, according to research presented at the 2023 SNMMI Annual Meeting.

• Molecular Imaging Identifies Brain Changes in Response to Food Cues; Offers Insight into Obesity Interventions

  Jun 27, 2023 — Molecular imaging with 18F-flubatine PET/MRI has shown that neuroreceptors in the brains of individuals with obesity respond differently to food cues than those in normal-weight individuals, making the neuroreceptors a prime target for obesity treatments and therapy.

• Genomics- and Image-Guided Subtyping Refines Characterization of Alzheimer’s Disease

  Jun 27, 2023 — A new computational technique that combines genomic and tau PET imaging data promises a more personalized approach for subtyping Alzheimer’s disease.

• Novel Theranostic Agent Targets Multiple Cancer Types

  Jun 27, 2023 — A newly discovered radionuclide-based agent (CB-2PA-NT) has been shown to have high tumor uptake, sustained tumor retention, and high contrast in preclinical models, making it a prime candidate for a novel theranostics approach.

• Personalized Dosing in Prostate Cancer Treatment Improves Patient Outcomes

  Jun 27, 2023 — By monitoring early-response biomarkers in men undergoing 177Lu-PSMA prostate cancer treatment, physicians can personalize dosing intervals, significantly improving patient outcomes.

• SNMMI Elects Jean-Luc C. Urbain, MD, PhD, FASNC, as Vice President-Elect at 2023 Annual Meeting

  Jun 26, 2023 — Jean-Luc C. Urbain, MD, PhD, FASNC, professor of radiology/nuclear medicine and medicine, vice chair of theranostics, and director of nuclear medicine at Roswell Park Cancer Center at the University of Buffalo in New York, has been elected vice president-elect for the SNMMI.

• Umar Mahmood, MD, PhD, Receives First Annual SNMMI Minoshima-Pappas Transformational Leadership Award

  Jun 26, 2023 — Umar Mahmood, MD, PhD, chief of Nuclear Medicine and Molecular Imaging, director of the Center for Precision Imaging, and associate chair for imaging sciences in the Department of Radiology at Massachusetts General Hospital and professor of radiology at Harvard Medical School in Boston, has been named as the first recipient of the new Minoshima-Pappas Transformational Leadership Award.

• SNMMI Elects Cathy Sue Cutler, PhD, FSNMMI, as President-Elect at 2023 Annual Meeting

  Jun 26, 2023 — Cathy Sue Cutler, PhD, FSNMMI, director of the medical isotope research and production program at Brookhaven National Laboratory in Upton, New York, has been named as president-elect for the SNMMI.

• New Radiopharmaceutical Therapy Target Identified for Metastatic Bladder Cancer

  Jun 26, 2023 — A new therapeutic target has been discovered for metastatic bladder cancer, opening up the door for more effective detection and treatment of this deadly disease.

• SNMMI Names Helen Nadel, MD, FRCPC, as President at 2023 Annual Meeting

  Jun 26, 2023 — Helen Nadel, MD, FRCPC, director of pediatric nuclear medicine at Lucile Packard Children’s Hospital at Stanford and clinical professor of radiology at the Stanford School of Medicine, in Stanford, California, has been named president of the SNMMI.

• SNMMI Image of the Year: New Theranostic Pair Facilitates Early Detection and Effective Treatment of Pancreatic Cancer

  Jun 26, 2023 — A first-in-human evaluation of the novel theranostic pair Ga-68 DOTA-5G / Lu-177 DOTA-ABM-5G has confirmed its ability to successfully detect metastatic pancreatic cancer and visualize targeted treatment of the disease. A grouping of the resulting images has been selected as the 2023 SNMMI Henry N. Wagner, Jr., Image of the Year.

• Novel Radiotracer Accurately Detects and Differentiates Renal Cell Carcinomas

  Jun 26, 2023 — A new PET tracer, Zr-89 DFO-girentuximab, can accurately detect a type of kidney cancer called clear cell renal cell carcinoma and differentiate it from other types of kidney tumors.

• Peter J. H. Scott, PhD, Receives SNMMI Sam Gambhir Trailblazer Award

  Jun 26, 2023 — Peter J. H. Scott, PhD, associate professor of radiology and pharmacology, division director of nuclear medicine, and director of the PET Center at the University of Michigan in Ann Arbor, Michigan, has been named as the 2023 recipient of the Sam Gambhir Trailblazer Award.

• Society of Nuclear Medicine and Molecular Imaging Announces 2023 Fellows

  Jun 26, 2023 — SNMMI recognized ten new SNMMI Fellows today during a plenary session at the society’s 2023 Annual Meeting.

• Henry VanBrocklin, PhD, FSNMMI, FSRS, Receives SNMMI 2023 Paul C. Aebersold Award for Outstanding Achievement in Basic Nuclear Medicine Science

  Jun 25, 2023 — Henry VanBrocklin, PhD, has been named the 2023 recipient of the prestigious Paul C. Aebersold Award.

• Translational PET Tracer Visualizes Brain Cholesterol Metabolism

  Jun 25, 2023 — A new PET radiotracer that visualizes the enzyme primarily responsible for metabolic cholesterol degradation in the brain has been successfully validated, according to research presented at the 2023 SNMMI Annual Meeting.

• SNMMI and IAC Collaborate on New Radiopharmaceutical Therapy Accreditation Program

  Jun 25, 2023 — SNMMI and the Intersocietal Accreditation Commission are pleased to announce an enhanced partnership that will help ensure quality care for patients receiving radiopharmaceutical therapy.

• Nizar A. Mullani, BS, Receives SNMMI 2023 Georg Charles de Hevesy Nuclear Pioneer Award

  Jun 25, 2023 — Nizar A. Mullani, BS, one of the pioneers of the first positron emission tomography (PET) prototype, has been named as this year’s recipient of the Georg Charles de Hevesy Nuclear Pioneer Award.

• SNMMI Announces Dmitry Beyder, CNMT, MPA, as President of the Technologist Section During 2023 Annual Meeting

  Jun 25, 2023 — Dmitry Beyder, CNMT, MPA, radiology program manager of nuclear medicine, PET, CT and patient transport at Barnes-Jewish Hospital/Mallinckrodt Institute of Radiology in St. Louis, Missouri, has been elected as the 2023-24 president for the SNMMI-TS.

• SNMMI Abstract of the Year: Novel Molecularly Targeted I-131 Apamistamab Enables Marrow Transplantation with Long-term Survival in Relapsed/Refractory Acute Myeloid Leukemia

  Jun 25, 2023 — Personalized dosing of Iomab-B (I-131 apamistamab), has been shown to successfully enable relapsed and/or refractory acute myeloid leukemia (AML) patients with active disease to successfully receive potentially life-saving bone marrow transplantation.

• FAPI PET Imaging Accurately Assesses Disease Activity in Rheumatoid Arthritis

  Jun 25, 2023 — PET imaging with Ga-68 FAPI offers a feasible, reliable, and reproducible method for evaluating disease activity in rheumatoid arthritis, according to new research presented at the 2023 SNMMI Annual Meeting.

• SNMMI Announces Julie Dawn Bolin, MS, CNMT, as President-Elect of the Technologist Section During 2023 Annual Meeting

  Jun 25, 2023 — Julie Dawn Bolin, MS, CNMT, program director of nuclear medicine technology at GateWay Community College in Phoenix, Arizona, and nuclear medicine technologist at Banner Staffing Services in Tucson, Arizona, has been elected 2023-24 president-elect for the SNMMI-TS.

• New PET Model for Quantifying Cardiac Amyloidosis Allows for More Accurate Diagnosis and Monitoring

  Jun 25, 2023 — Researchers have identified the optimal tracer kinetic model to quantify 18F-flutemetamol myocardial uptake in patients with transthyretin (ATTR) cardiac amyloidosis.

• Ultra-High Resolution Brain PET Scanner Visualizes and Quantifies Brainstem Nuclei for the First Time

  Jun 24, 2023 — A new ultra-high resolution (UHR) brain PET scanner may have the ability to characterize previously indistinguishable brain regions that are known to be involved in Alzheimer’s disease, depressive disorders, visual attention disorders, tinnitus, and other conditions.

• New Whole-Body PET Technology Offers Cost-Effective Solution to Improve Image Resolution and Sensitivity

  Jun 24, 2023 — A newly developed technology called “augmented whole-body scanning via magnifying PET” (AWSM-PET) has been shown to enhance the image resolution and system sensitivity of clinical whole-body PET/CT imaging.

• Nuclear Medicine Global Initiative Reports Worldwide Challenges and Opportunities in Theranostics Education

  Jun 23, 2023 — Leaders from 12 nuclear medicine organizations around the world have issued a white paper about the challenges and opportunities in theranostics education.

• Pretherapy Imaging and Dosimetry Offer Personalized Treatment Planning for Thyroid Cancer Patients

  Jun 22, 2023 — JNM: A combination of pretherapy imaging and dosimetry can help ensure that patients with refractory differentiated thyroid cancer obtain the maximum benefit from radioactive iodine treatments following redifferentiation therapy.

• Novel Imaging Agent Allows for Earlier Detection of Progressive Pulmonary Fibrosis

  Jun 20, 2023 — JNM: A newly developed PET imaging agent can non-invasively identify pulmonary fibrosis in its early stages, reducing the need for unnecessary biopsies and allowing patients to begin treatment sooner.

• Interested in the Nuclear Medicine Career Interest Program?

  Jun 20, 2023 — This interest program information session gives students the opportunity to learn about job details, educational requirements and opportunities available for a future career in nuclear medicine.

• Ellison, Scott and Sanford Receive SNMMI Mars Shot Fund Award

  Jun 12, 2023 — SNMMI is excited to announce Paul Ellison, PhD, Peter J. H. Scott, PhD, and Melanie S. Sanford, PhD, have been selected as the recipients of a $500,000 grant from the 2023 Mars Shot Fund.

• Randy Yeh, MD, Receives SNMMI Mars Shot Fund Award

  Jun 7, 2023 — SNMMI is excited to announce that Randy Yeh, MD, has been selected as the recipient of a $500,000 grant from the 2023 Mars Shot Research Fund.

• Amir Iravani, MD, Receives SNMMI Mars Shot Fund Award

  Jun 7, 2023 — SNMMI is excited to announce that Amir Iravani, MD, has been selected as the recipient of a $1,000,000 SNMMI Mars Shot Fund Grant.

• Julie Sutcliffe, PhD, Receives SNMMI Mars Shot Fund Award

  Jun 7, 2023 — SNMMI is excited to announce that Julie Sutcliffe, PhD, has been selected as the recipient of a $500,000 grant from the 2023 Mars Shot Fund.

• Craig Levin, PhD, Receives SNMMI Mars Shot Fund Award

  Jun 7, 2023 — SNMMI is excited to announce that Craig Levin, PhD, has been selected as the recipient of a $500,000 grant from the 2023 Mars Shot Fund.

• Amino Acid PET Successfully Differentiates Recurrent Brain Metastases, Reducing Invasive Procedures and Overtreatment

  May 12, 2023 — A new meta-analysis indicates that amino acid PET can accurately differentiate recurrent or progressive brain metastases from treatment-related changes, potentially reducing overtreatment, according to research published in May JNM.

• New Research: FAPI PET Imaging Superior for Diagnosing Multiple Types of Cancer, with Potential for Targeted Treatment

  May 1, 2023 — Two articles in the May issue of JNM illustrate the promise of the novel FAPI radiotracer. Results from the largest study of patients undergoing 68Ga-FAPI PET demonstrate the superiority of 68Ga-FAPI over standard 18F-FDG PET in evaluating multiple types of cancer. In a separate study, a newly designed FAPI-targeted treatment was found to suppress tumor growth in several common cancers in a preclinical setting. These advances have strong potential to provide more precise staging and management for cancer patients.

• Newly Developed PSG Score Improves Patient Selection for PSMA Radiopharmaceutical Therapy

  Apr 19, 2023 — International, multicenter testing demonstrated the effectiveness of a newly established PSMA PET scoring system that can successfully predict whether metastatic castration-resistant prostate cancer patients will respond to treatment with Lu-177 PSMA therapy. The research was published online in JNM.

• JNM Publishes Appropriate Use Criteria for Lymphoscintigraphy in Sentinel Node Mapping and Lymphedema/Lipedema

  Apr 14, 2023 — SNMMI and 10 other professional societies have issued appropriate use criteria for lymphoscintigraphy in sentinel node mapping and lymphedema/lipedema. The criteria are summarized in the April issue of JNM.

• New Nuclear Medicine Therapy Cures Human Non-Hodgkin Lymphoma in Preclinical Model

  Apr 11, 2023 — A single dose of the radioimmunotherapy can cure human non-Hodgkin lymphoma in an animal model, according to research published in the April issue of The Journal of Nuclear Medicine.

• Blood-Based Biomarkers Accurately Predict Neuroendocrine Tumor Response to Radiopharmaceutical Therapy

  Apr 6, 2023 — A simple blood draw can provide physicians with valuable information about whether PRRT is likely to be effective in a patient with neuroendocrine cancer—opening new possibilities for tailoring radiopharmaceutical treatment to patients. The research is published in the April issue of JNM.

• Molecular Imaging Offers Insight Into Chemo-Brain

  Mar 28, 2023 — A new literature review sheds light on how nuclear medicine brain imaging can help evaluate the biological changes that cause chemotherapy-related cognitive impairment (CRCI), commonly known as chemo-brain. This information—published ahead-of-print in JNM—can help patients better understand the changes in their cognitive status during and after treatment.

• JNM Explores Potential Applications for ChatGPT in Nuclear Medicine and Molecular Imaging

  Mar 27, 2023 — In a new JNM article, Irène Buvat, PhD, and Wolfgang Weber, MD, PhD, explore the potential for using AI chatbot ChatGPT in the field of nuclear medicine and molecular imaging.

• PSMA PET Improves Decision Making for Prostate Cancer Treatment

  Mar 24, 2023 — PSMA PET mapping of cancer recurrence in the prostate bed shows that current radiotherapy contouring guidelines—which determine the target areas for treatment—miss a significant number of lesions and may unnecessarily irradiate healthy tissues, according to a new study published ahead of print in JNM. Researchers are calling for redefinition of the guidelines to improve patient outcomes.

• New Compact and Low-Cost Lensless Radiomicroscope Developed for Nuclear Medicine Imaging

  Mar 21, 2023 — A novel, palm-sized imaging modality that can visualize the distribution of medical radiopharmaceuticals with very fine resolution has been developed and successfully tested, according to research published in March JNM. Known as the lensless radiomicroscope, the instrument offers the same level of imaging performance as its closest imaging equivalent but comes with significantly larger field of view and costs less than $100.

• Novel PET Radiotracer Successfully Detects Multiple Cancers, Offers Potential for New Targeted Radionuclide Therapy

  Mar 16, 2023 — A new radiotracer, Ga-68 FAP-2286, has been found to be more effective than the most commonly used nuclear medicine cancer imaging radiotracer, F-18 FDG, according to a study published in JNM. Ga-68 FAP-2286 detected 100 percent of primary tumors across multiple cancer types as compared to F-18 FDG, which identified only 80 percent. Ga-68 FAP-2286 was also more effective in detecting lymph node metastases and distant metastases.

• SNMMI Applauds Introduction of FIND Act of 2023: Legislation Will Ensure Patient Access to Innovative and Effective Diagnostic Imaging

  Mar 6, 2023 — SNMMI, along with more than 80 stakeholder organizations, supports and applauds the introduction of H.R. 1199, the Facilitating Innovative Nuclear Diagnostic (FIND) Act of 2023. The legislation will ensure patient access to innovative and effective diagnostic imaging.

• SNMMI Mars Shot/Lobular Breast Cancer Alliance Announce Recipient of the Invasive Lobular Carcinoma Imaging Research Fellowship

  Mar 1, 2023 — The SNMMI Mars Shot Research Fund and the Lobular Breast Cancer Alliance (LBCA) are excited to announce that Marina Sharifi, MD, PhD, has been selected as the recipient of the joint SNMMI/LBCA Invasive Lobular Carcinoma Imaging Research Fellowship.

• JNM Publishes Procedure Standard/Practice Guideline for SSTR PET Imaging of Neuroendocrine Tumors

  Feb 21, 2023 — SNMMI and the European Association of Nuclear Medicine (EANM) have issued a new procedure standard/practice guideline to assist physicians in recommending, performing, interpreting, and reporting the results of somatostatin receptor (SSTR) PET imaging for patients with neuroendocrine tumors. The guideline is published in the February issue of The Journal of Nuclear Medicine.

• New Dual-Phase Imaging Protocol Reduces Costs and Radiation Exposure for Cognitively Impaired Patients

  Feb 8, 2023 — A new nuclear medicine imaging protocol can assess both amyloid and neurodegeneration with a single tracer injection, cutting costs and radiation exposure for patients as well as providing them greater comfort. This research was published in the February issue of The Journal of Nuclear Medicine.

• E-Cigarettes Potentially Harmful: PET Imaging Shows Greater Lung Inflammation in E-Cigarette Users Than Cigarette Smokers

  Jan 25, 2023 — PET imaging shows greater lung inflammation in e-cigarette users than in cigarette smokers, according to a new study published ahead of print in JNM.

• Nearly Half of Medicare Patients with Non-Small Cell Lung Cancer Not Staged According to National Guidelines: Lack of Adherence Linked to Greater Mortality Rates

  Jan 17, 2023 — A study published in the January JNM reports that approximately half of Medicare patients with NSCLC do not receive the appropriate imaging prior to radiation therapy. Significant improvement in survival rates was found in patients who had FDG PET/CT imaging—as recommended in NCCN guidelines—compared to those who underwent CT imaging alone.

• Novel PET Radiotracer Reduces Number of False-Positive Cancer Findings After COVID-19 Vaccination

  Jan 10, 2023 — A novel imaging agent, Ga-68 FAPI, can reduce the number of false-positive PET/CT findings among cancer patients recently vaccinated for COVID-19, helping prevent costly follow-up and false management decisions for cancer patients.

• PSMA PET/MRI Accurately Predicts Risk of Prostate Cancer Recurrence

  Jan 5, 2023 — In men recently diagnosed with intermediate or high-grade prostate cancer, PSMA PET/MRI can successfully determine whether their cancer is likely to return within two years of a prostatectomy.

• Nuclear Medicine Bone Scan Study Identifies Prevalence and Outcomes of Cardiac Amyloidosis

  Jan 3, 2023 — Approximately 3% of bone scan patients have markers of cardiac amyloidosis, which can lead to heart failure and increased mortality, according to new research published in JNM. This incidental finding may offer a window of opportunity for treatment.

• Novel PET Agent Effectively Detects Multiple Cancers, Identifies Patients for Targeted Therapies

  Nov 17, 2022 — A new molecular imaging radiotracer, Ga-68 PentixaFor, can precisely diagnose a variety of cancers, providing a roadmap to identify patients who may benefit from targeted radionuclide therapies.

• PET/MRI Machine Learning Model Can Eliminate Sentinel Lymph Node Biopsy in Majority of Breast Cancer Patients

  Nov 10, 2022 — Nearly 70 percent of breast cancer patients could find out if their cancer has spread to their lymph nodes without having to undergo an invasive sentinel node biopsy, according to new research published in JNM.

• CTN: Enabling Accurate Quantitative PET/CT and SPECT/CT Imaging

  Oct 25, 2022 — Quantitative measurements have long been a strength of nuclear medicine. There is renewed urgency for accurate, reproducible, and standardized measurements in routine clinical practice as the role of diagnostic and therapeutic radiopharmaceuticals in clinical trials and routine clinical care grows. The CTN continues to be involved in this space, with several active projects to address this need.

• Novel PET Imaging Agent Detects Earliest Signs of Alzheimer’s Disease

  Oct 19, 2022 — A new highly selective PET imaging agent can detect the presence of overexpressed monoamine oxidase-B (MAO-B) in cognitively unimpaired individuals with high beta amyloid, according to research published in the October issue of JNM.

• Ultra-Low Dose Total Body PET/CT Effective for Evaluating Arthritis

  Oct 12, 2022 — Total body PET/CT scans can successfully visualize systemic joint involvement in patients with autoimmune arthritis, according to new first-in-human research published in the October issue of JNM.

• SNMMI and the Lobular Breast Cancer Alliance Announce $100,000 Research Grant

  Oct 3, 2022 — SNMMI announces a new $100,000 grant to fund research on nuclear medicine imaging and treatments for lobular beast cancer. The grant is sponsored by the SNMMI Mars Shot Fund and the Lobular Breast Cancer Alliance.

• New PET Tracer Shows Promise for uPAR-Targeted Therapy of Neuroendocrine Neoplasms

  Sep 28, 2022 — A novel PET radiotracer can accurately assess the presence of a biomarker that indicates the level of tumor aggressiveness in neuroendocrine neoplasms, according to research published in September JNM, and may also serve as a potential target for peptide radionuclide therapy (PRRT) for NEN patients.

• TerraPower Announces Funding Raised for Nuclear Technologies

  Sep 20, 2022 — TerraPower, a nuclear innovation company founded by Bill Gates, announced a $750 million funding raise co-led by Gates and SK, a large South Korean conglomerate that is one of South Korea’s largest energy providers. According to a press release from TerraPower, this effort will enhance the company’s “groundbreaking work in advanced nuclear energy technologies and nuclear medicine.”

• SNMMI PR Campaign Lands Stories in Major Media Markets

  Sep 12, 2022 — SNMMI’s consumer-focused public relations initiative to raise awareness about what nuclear medicine is and what it can accomplish has seen continued success in the summer months.

• A Special Issue of the Journal of Nuclear Medicine Technology Highlights the New Frontier of Theranostics

  Sep 12, 2022 — A special issue of the Journal of Nuclear Medicine Technology focuses on theranostics as it relates to technologists and includes articles on quality and practice management, imaging, and radiation safety, as well as continuing education articles.

• New Research Shows PSMA PET/CT Imaging Changes Management for Close to 50 Percent of Prostate Cancer Patients

  Sep 7, 2022 — In prostate cancer patients experiencing recurrence following a radical prostatectomy, imaging with 18F-DCFPyL PSMA PET/CT has been shown to considerably improve detection of active disease as compared to imaging with CT alone.

• Crosby Elected Vice Chair of Patient Advocacy Advisory Board for the Society of Nuclear Medicine and Molecular Imaging

  Aug 11, 2022 — Mike Crosby of San Diego, California, has been elected to a two-year term as vice chair of SNMMI's Patient Advocacy Advisory Board.

• Francoeur to Lead Patient Advocacy Advisory Board for Society of Nuclear Medicine and Molecular Imaging

  Aug 11, 2022 — Jeri Francoeur of Ormond Beach, Florida, has been elected to a two-year term as chair of SNMMI's Patient Advocacy Advisory Board.

• Journal of Nuclear Medicine Impact Factor Rises Again

  Jun 29, 2022 — The Journal of Nuclear Medicine has again achieved the highest impact factor in its history, ranking fourth among all medical imaging journals worldwide, according to new data just released in Clarivate's 2021 Journal Citation Reports.

• Revolutionary Technology Shortens Cardiac Scan Time, Provides High-Quality SPECT Images

  Jun 14, 2022 — A cardiac SPECT imaging system performs scans 10 to 100 times faster than current SPECT systems, according to new research presented at the Society of Nuclear Medicine and Molecular Imaging 2022 Annual Meeting.

• PSMA PET Highlights Need for Updated Prostate Cancer Therapy Guidelines

  Jun 14, 2022 — Current guidelines used to plan salvage radiation treatments in patients with local recurrence of prostate cancer should be updated to take into consideration information derived from novel imaging modalities, such as PSMA PET.

• SNMMI Image of the Year: New Biomarker Predicts Severity of Cardiac Remodeling after Heart Attack

  Jun 14, 2022 — Poor functional outcomes after a heart attack can be predicted with a new PET imaging agent, Ga-68-FAPI-46. The detailed depiction of Ga-68-FAPI-46 PET signal after acute anterior myocardial infarction has been selected as SNMMI’s 2022 Image of the Year.

• SNNMI Abstract of the Year: Targeted Radionuclide Treatment Achieves High Response Rate, Minimal Toxicities for Advanced-Stage Neuroendocrine Tumors

  Jun 14, 2022 — A targeted radionuclide alpha therapy, Ac-225 DOTATATE, has been shown to have long-term anti-tumor effects in patients with advanced-stage gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

• Novel Radiopharmaceutical Pair Detects and Treats Melanoma; Study Shows Potential for Broad Application in Solid Tumors

  Jun 14, 2022 — A newly developed small-molecular radiopharmaceutical pair has successfully visualized and treated melanoma in a preclinical study, according to new research presented at the Society of Nuclear Medicine and Molecular Imaging 2022 Annual Meeting.

• SNMMI Elects Cathy Sue Cutler, PhD, FSNMMI, as Vice President-Elect at 2022 Annual Meeting

  Jun 13, 2022 — Cathy Sue Cutler, PhD, FSNMMI, director of the medical isotope research and production program at Brookhaven National Laboratory in Upton, New York, has been named as vice president-elect for the Society of Nuclear Medicine and Molecular Imaging.

• SNMMI Announces Krystle W. Glasgow, MIS, CNMT, NMTCB(CT), NMAA, FSNMMI-TS, as President of the Technologist Section During 2022 Annual Meeting

  Jun 13, 2022 — Krystle W. Glasgow, MIS, CNMT, NMTCB(CT), NMAA, FSNMMI-TS, instructor and clinical coordinator at the University of Alabama at Birmingham in Birmingham, Alabama, has been elected as the 2022-23 president for the Society of Nuclear Medicine and Molecular Imaging Technologist Section (SNMMI-TS).

• SNMMI Elects Munir Ghesani, MD, FACNM, FACR, as President at 2022 Annual Meeting

  Jun 13, 2022 — Munir Ghesani, MD, FACNM, FACR, chief of nuclear medicine and molecular imaging at Mount Sinai Health System and associate professor of radiology at Mount Sinai Hospital in New York, NY, has been named as president for the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

• Andrei Iagaru, MD, FACNM, Receives Inaugural SNMMI Sam Gambhir Trailblazer Award

  Jun 13, 2022 — Andrei Iagaru, MD, FACNM, professor of radiology (nuclear medicine) and chief of the Division of Nuclear Medicine and Molecular Imaging at Stanford University, in Stanford, California, has been named as the first recipient of the Sam Gambhir Trailblazer Award.

• SNMMI Announces Dmitry Beyder, CNMT, MPA, as President-Elect of the Technologist Section During 2022 Annual Meeting

  Jun 13, 2022 — Dmitry Beyder, CNMT, MPA, radiology program manager of nuclear medicine, PET, CT and patient transport at Barnes-Jewish Hospital/Mallinckrodt Institute of Radiology in St. Louis, Missouri, has been elected as the 2022-23 president-elect for the Society of Nuclear Medicine and Molecular Imaging Technologist Section (SNMMI-TS).

• SNMMI Launches Mars Shot Fund for Nuclear Medicine Research; Initial Donations Top $600,000

  Jun 13, 2022 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) today announced the creation of the Mars Shot Fund, an initiative to raise $100 million to help pay for research into nuclear medicine, molecular imaging, and therapy.

• Society of Nuclear Medicine and Molecular Imaging Announces 2022 Fellows

  Jun 13, 2022 — The Society of Nuclear Medicine and Molecular Imaging recognized 15 new SNMMI Fellows on Monday, June 13, during a plenary session at the society’s 2022 Annual Meeting.

• Simon R. Cherry, PhD, Receives 2022 Benedict Cassen Prize for Research in Molecular Imaging

  Jun 13, 2022 — Simon R. Cherry, PhD, known for his pioneering work in the development of PET technology and co-development of the EXPLORER total-body PET/CT scanner, was awarded the Benedict Cassen Prize during the Society of Nuclear Medicine and Molecular Imaging 2022 Annual Meeting.

• Molecular Imaging Biomarker Predicts Response to CAR T Cell Therapy

  Jun 12, 2022 — A new PET imaging agent, F-18 AlF-FAPI-74, has been found to effectively monitor and predict treatment response of CAR T cell therapy. This non-invasive imaging approach has the potential to help inform important clinical decision-making early in the course of treatment—including re-dosing of therapy, dose optimization, change of therapeutic course, and many more—to optimize patient outcomes.

• Markus Schwaiger, MD, Receives SNMMI Georg Charles de Hevesy Nuclear Pioneer Award

  Jun 12, 2022 — Markus Schwaiger, MD, a scientist known for his contributions to cardiac PET imaging, has been named as this year’s recipient of the Georg Charles de Hevesy Nuclear Pioneer Award.

• Robert H. Mach, Phd, Receives SNMMI 2022 Paul C. Aebersold Award for Outstanding Achievement in Basic Nuclear Medicine Science

  Jun 12, 2022 — Robert H. Mach, PhD, has been named the 2022 recipient of the prestigious Paul C. Aebersold Award.

• Virtual CT Scans Cut Patient Radiation Exposure in Half During PET/CT Studies

  Jun 12, 2022 — A novel artificial intelligence method can be used to generate high-quality “PET/CT” images and subsequently decrease radiation exposure to the patient.

• PET/CT Effective in Evaluating and Monitoring Post-COVID-19 Lung Disease

  Jun 11, 2022 — F-18 FDG PET/CT has been proven successful in evaluating lung inflammation and monitoring treatment effects in patients suffering from post-COVID-19 lung disease.

• PET Imaging Confirms Link Between Obstructive Sleep Apnea and Heart Blood Flow Impairment

  Jun 11, 2022 — Patients with severe obstructive sleep apnea (OSA) are less able to increase blood flow to the heart when needed, according to a first-of-its-kind PET imaging study presented at the Society of Nuclear Medicine and Molecular Imaging 2022 Annual Meeting.

• Novel Ultra-Low Dose PET Technique Significantly Reduces Radiation Exposure

  Jun 11, 2022 — A new PET imaging technique can greatly reduce the amount of patient radiation exposure by eliminating the need for an accompanying CT scan. Without the CT scan, the amount of radiation delivered to the patient is cut dramatically, which benefits all patients, but in particular the pediatric population and those in need of multiple scans.

• Novel PET Agent Highly Effective for Imaging Meningiomas; Offers Logistical Advantages Over Standard Agents

  Jun 11, 2022 — A novel somatostatin-receptor (SSTR) targeting peptide—18F-SiTATE—has been shown to provide excellent imaging in patients with meningiomas, identifying bone involvement and lesions previously undetected on standard morphological imaging.

• New Targeted Radionuclide Alpha Therapy Improves Prostate Cancer Outcomes

  Jun 11, 2022 — A novel targeted radionuclide alpha therapy for metastatic castration-resistant prostate cancer—225AC-NM600—has been shown to achieve significantly better outcomes than its corresponding targeted radionuclide beta therapy.

• Active Brown Adipose Tissue Protects Against “Pre-Prediabetes”

  May 4, 2022 — In a prospective study of young, lean adults, PET/CT imaging revealed that higher levels of active brown adipose tissue (also known as “brown fat”) are more prevalent in individuals who exhibit very early indications of metabolic disorders. The research was published ahead of print in The Journal of Nuclear Medicine.

• JNM Publishes Joint Guide for the Establishment of Theranostics Centers

  Apr 29, 2022 — SNMMI, the European Association of Nuclear Medicine, and the International Atomic Energy Agency have created a new guide for the creation of dedicated theranostics centers.

• Novel Deep Learning Method Provides Early and Accurate Differential Diagnosis for Parkinsonian Diseases

  Apr 21, 2022 — A new deep learning method has been created to aid in the diagnosis of parkinsonian diseases, according to research published in JNM.

• New ASNC/SNMMI Training Course Helps Physicians Meet U.S. Requirements for Handling Medical Radioisotopes

  Apr 12, 2022 — SNMMI and ASNC have released a new “80 Hour Radionuclide Authorized User Training Course” for nuclear medicine physicians, which will fulfill the 80 hours of classroom training required by the NRC and Agreement States for physicians to become Authorized Users.

• SNMMI Releases Statement on CMS Final Decision for Alzheimer’s Disease Coverage

  Apr 8, 2022 — CMS has announced its final decision on coverage of monoclonal antibodies to treat Alzheimer’s disease. It includes no additional coverage for beta amyloid PET scans, which will continue to be limited to one per patient per lifetime.

• New Radionuclide Combination Therapy Safe and Effective in Metastatic Prostate Cancer Patients

  Apr 7, 2022 — A novel nuclear medicine combination therapy has been proven safe and effective in men with heavily pre-treated metastatic castration-resistant prostate cancer. The research was published in the April issue of JNM.

• SNMMI Applauds FDA Approval of New Metastatic Prostate Cancer Treatment

  Mar 23, 2022 — SNMMI applauds the FDA's approval of a new, game-changing nuclear medicine treatment for metastatic prostate cancer shown to reduce risk of death by 38% and risk of progression by 60% in mCRPC patients.

• Molecular Imaging Uncovers Effects of COVID-19 on the Brain

  Mar 15, 2022 — A significant number of COVID-19 neurological complications—such as fatigue, headache, and cognitive impairment—are ultimately reversible, according to new research in The Journal of Nuclear Medicine.

• SNMMI Designates First Radiopharmaceutical Therapy Centers of Excellence

  Mar 10, 2022 — SNMMI has named Stanford Health Care and the Dana-Farber Brigham Cancer Center as its first two designated Radiopharmaceutical Therapy Centers of Excellence.

• Novel Radioligand Therapy Proven Superior for Metastatic Prostate Cancer Patients

  Mar 9, 2022 — A novel prostate cancer treatment—Ac-225 PSMA-617 radioligand therapy—has been shown to increase the progression free survival and overall survival of metastatic castration-resistant prostate cancer patients, according to research published by JNM.

• SNMMI Launches New Quality Systems Personnel Training Program

  Jan 31, 2022 — SNMMI has launched the Quality Systems Personnel Training Program (QSPTP) to educate, train, and develop individuals with a pharmacy or chemistry background in the production and release of clinical radiopharmaceuticals.

• PSMA PET Validates EAU Classification System to Determine Risk of Prostate Cancer Recurrence

  Jan 20, 2022 — Research published in the January issue of JNM has confirmed the accuracy of the European Association of Urology risk classification system that groups prostate cancer patients based on their risk of recurrence.

• SNMMI Reacts to CMS Coverage Decision on New Alzheimer’s Therapy

  Jan 12, 2022 — On January 11, CMS announced that it proposes to cover FDA-approved monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s disease under CED in CMS-approved randomized controlled trials. SNMMI reacts.

• PET/CT Artificial Intelligence Model Ideal for Predicting Risk of Future Heart Attack

  Jan 11, 2022 — When assessed together in an AI model, coronary F-18 NaF uptake on PET and quantitative coronary plaque characteristics on CT angiography were found to provide risk prediction superior to that of clinical data alone.

• JNM Publishes Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging

  Jan 7, 2022 — SNMMI and peer medical groups have issued AUC for PSMA PET imaging. Published in the January issue of JNM, the criteria are the product of an international multidisciplinary panel of expert healthcare providers.

• Senate Passes Protecting Medicare and American Farmers from Sequester Cuts Act

  Dec 10, 2021 — Last night, SNMMI and more than 300 medical societies rejoiced when the Senate passed the Protecting Medicare and American Farmers from Sequester Cuts Act (S. 610).

• New Theranostic Approach Reduces Tumor Volume and Increases Survival in Neuroendocrine Tumor Study

  Dec 15, 2020 — A pair of copper radionuclides that target the somatostatin receptor overexpressed in neuroendocrine tumors has proven successful in identifying tumors and improving survival, according to new research published in JNM.

• The Journal of Nuclear Medicine Celebrates 60 Years of Research

  Dec 9, 2020 — The Journal of Nuclear Medicine (JNM) has issued a special supplement commemorating six decades of leadership in the field of nuclear medicine, molecular imaging and therapy.

• PET Imaging Tracer Proves Effective for Diagnosing and Managing Rare CNS B-Cell Lymphoma

  Dec 9, 2020 — PET imaging with Ga-68-pentixafor is an effective diagnostic tool for central nervous system B-cell lymphoma, according to a proof-of-concept study published in the December issue of JNM.

• FDA Announces First-Ever Approval of PSMA PET for Prostate Cancer Imaging

  Dec 2, 2020 — The FDA has approved ga-68 PSMA-11 for PET imaging of PSMA–positive lesions in men with prostate cancer. It is the first approval for a PSMA PET drug in the United States.

• Multi-Center, Multi-Tracer PET Studies Harmonized to Detect Neuroinflammation in ALS

  Dec 1, 2020 — A novel ALS (amyotrophic lateral sclerosis) study has pooled data from multiple sites to effectively visualize neuroinflammation, which is key to developing drugs to treat the disease.

• New Radiotracer Can Identify Nearly 30 Types of Cancer: Future potential for therapeutic application

  Jun 7, 2019 — A novel class of radiopharmaceuticals has proven effective in non-invasively identifying nearly 30 types of malignant tumors, according to research published in the June issue of The Journal of Nuclear Medicine.